The Association between Liver Metastasis of Non-Small Cell Lung Cancer and Prognosis Based on Immunotherapy: A Secondary Summary analysis of Individual Patient Data from Randomized Trials

Lung cancer is a serious disease that affects many people around the world. When lung cancer spreads to the liver, the chances of survival are very low, with most patients living only about three months after diagnosis. This is a big concern, as lung cancer is one of the most common types of cancer and impacts thousands of individuals and their families each year.

Recent studies show that combining chemotherapy, which uses strong drugs to kill cancer cells, with immunotherapy, which helps the body's immune system fight cancer, can lead to better results for patients with lung cancer that has spread to the liver. However, we still have questions. For example, we don’t know if adding extra immunotherapy for patients with liver metastases (cancer spread) is better than for those without. We also need to find out which patients with liver metastases will benefit the most from treatment and when immunotherapy should be given and discontinued.

Our research aims to answer these important questions. We want to understand which patients with lung cancer and liver metastases will get the best results from treatment and the best timing for immunotherapy. By figuring this out, we hope to improve treatment plans and patient care.

To conduct our research, we will look closely at data from past clinical trials that involved patients with lung cancer that has spread to the liver. We will compare outcomes for different treatment combinations, including chemotherapy alone and the combination of chemotherapy and immunotherapy. By analyzing these results, we hope to identify patterns that can help doctors choose the most effective treatments.

This research is important because it will help improve the understanding of how to treat lung cancer that has spread to the liver. Our findings could lead to better survival rates and a higher quality of life for those affected by this challenging condition.